Now that production of its next generation award-winning controlled-release cannabidiol (CBD) functional chewing gum, CanChew Plus™, has kicked off, Axim Biotechnologies (OTCQB: AXIM) has boosted its diverse billion-dollar product portfolio with another strong growth brand. With so many golden eggs in its brand basket, the company is expecting strong top line growth in the near future. Current revenue projections show AXIM could soon earn the rarified rank of unicorn.

AXIM is looking ahead to a bright future with an uplisting to either the NYSE or NASDAQ. The company’s strong sales projections are built on a number of factors. The company’s vertically-integrated supply chain speeds up logistics and reduces costs. It also facilitates full manufacturing capabilities at facilities in Almere in The Netherlands. AXIM has a healthy intellectual property (IP) portfolio that includes over 10 patents and over 20 trademarks, and the company has close to 20 products in various developmental stages.

AXIM’s product line is based on hemp, a cousin to marijuana classified under the same botanical category of cannabis sativa. The major difference between the two is that marijuana has significant amounts of tetrahydrocannabinol (THC) (5–20%), a psychotropic cannabinoid that will get you ‘high’. Hemp, on the other hand, has virtually no THC (less than 0.3%), but it is rich in cannabidiol (CBD) and cannabigerol (CBG).

Both CBD and CBG appear to offer benefits in treating some medical conditions. The AXIM product pipeline includes drug candidates to treat multiple sclerosis/pain spasticity, Parkinson’s disease, dementia, restless legs syndrome (RLS), Crohn’s disease, opioid addiction/cannabis dependence, tobacco smoking cessation, post-herpetic neuralgia, irritable bowel syndrome (IBS), inflammatory bowel disease, psoriasis/atopic dermatitis, glaucoma, and dry eye.

CanChew®, which contains 50 mg of hemp oil and 10 mg of CBD, is meant to alleviate IBS and inflammatory bowel disease. It is the world’s first patented controlled-release cannabinoid chewing gum. The new formulation, CanChew Plus™, contains the same active ingredients and is 60 percent smaller than the original CanChew® gums for an improved chewing experience. In addition, CanChew Plus™ offers an improved oral mucosal delivery system through microencapsulation that increases the bioavailability of the active ingredient from less than 50 percent, with CanChew®, to an absorption rate of 80 percent of CBD, after just 30 minutes of chewing.

In 2017, Axim plans to release CanChew® chewing gum as a food supplement. The company also intends to initiate a number of clinical studies for the product, including its evaluation in treating chronic pain and spasticity in patients with multiple sclerosis.

Currently trading at just under $10.00, the stock, under the symbol AXIM, peaked at $19.00 earlier this year. The folks at Motley Fool think it’s a good bet (http://dtn.fm/RK2ew), surmising that ‘investors were excited about the potential for Axim’s hemp-based chewing gum.’ They also called it ‘one of the best marijuana stocks this year’ in a 2016 report. Axim might just repeat that performance in 2017.

For more information, visit www.AximBiotech.com

SinglePoint, Inc. (OTC: SING) has a considerable stake in the state of the legal cannabis industry. Among other things, SinglePoint is a holding company for SingleSeed, a company that provides payment services, solutions, and support for the cannabis industry. Working in tandem, SinglePoint and SingleSeed share resources and offer non-cash payment solutions, such as: Pay by Text solutions that allow customers to pay for products using their mobile phones; point of sale terminals that provide customers the convenience of using debit/credit cards right at checkout; text mobile marketing solutions; and text message marketing.

SingleSeed exists to inform and educate shopkeepers and customers on vital issues in the retail and medicinal cannabis markets while also helping to legitimize the industry. The company strives to stay ahead of industry changes and continuously innovates and improves its tools and technologies, in large part, so it can help cannabis shopkeepers become better business owners.

Up until a couple of years ago, SinglePoint primarily provided mobile solutions for small to mid-size businesses, nonprofits and religious organizations. Among other things, the corporation offered mobile payment, marketing and technology solutions for these industries, and it enabled its clients to conduct business transactions, accept donations, and engage in targeted communications through mobile devices.

Then, two years ago, SinglePoint identified a vast business opportunity in the provision of credit card payment processing to merchants engaging in the cannabis industry and installed cashless ATMs at some 200 medical and recreational dispensaries spread throughout Colorado and Washington State. So far, bureaucracy at the federal government level has kept this business on hold, yet the company’s network of clients is expected to prove invaluable if and when regulators open up the market by giving the company an ‘in’ to payment processing for cannabis clients.

Fast-forward to today, the company maintains its cashless ATM terminals as a way for clients to get a cash advance to finance cannabis purchases. It is also using www.SingleSeed.com to compile a list of interested clients, and it has a connect-by-text marketing platform that enables cannabis businesses to communicate directly with customers in a way that adheres with strict cannabis-related marketing regulations.

The reality of a marijuana industry served by the commercial banking industry is one that SinglePoint and SingleSeed are both chasing. SinglePoint, through SingleSeed Payments, already offers payment processing solutions, mobile marketing services and more for the cannabis industry. It also has plans to acquire and invest in other companies operating within this space. As such, the establishment of a truly “bankable” marijuana industry would have far-reaching, profitable implications for both of these companies.

For more information, visit the company’s website at www.Singlepoint.com

Let us hear your thoughts: Singlepoint, Inc. Message Board

New forms of treatment based on monoclonal antibodies show a lot of promise for human immunodeficiency virus patients with drug resistance or limited treatment options, according to HIV/AIDS researchers at this year’s edition of the Conference on Retroviruses and Opportunistic Infections (CROI 2017), which was held last month in Seattle (http://nnw.fm/Co5Ma). Researchers focused on two monoclonal antibody therapies – PRO 140 from CytoDyn Inc. (OTCQB: CYDY) and Ibalizumab from TaiMed Biologics, both of which have shown impressive results during clinical trials as long-acting therapies for HIV patients with limited options because of HIV drug resistance.

PRO 140 is currently in two Phase 3 clinical trials and has several potential benefits compared to regular HIV therapies, including minimal side effects, hardly any toxicity, and less frequent dosing. Part of a new class of therapeutics designed to protect healthy cells from viral infection, PRO 140 in its current form is administered by weekly subcutaneous injection, and all of the research so far has indicated that it can maintain viral suppression for a long time (current patients on PRO 140 single agent therapy are going more than two years). PRO 140 works by blocking one of the two co-receptors the human immunodeficiency virus uses to enter cells – CCR5. It is estimated that about 70 percent of HIV patients in the United States and Europe and up to 90 percent of newly diagnosed cases carry a CCR5-using form of the virus (R5 strain of HIV).

Details of the innovative therapy, which has been granted fast track candidate status by the U.S. Food and Drug Administration, were presented at CROI 2017 by Amarex Clinical Research’s Dr. Kush Dhody, who oversees CytoDyn’s clinical trials. An early study of PRO 140 and its effects showed that a single IV infusion generated significant antiviral activity, while a follow-up study showed that weekly subcutaneous PRO 140 injections also reduced viral load exponentially. Most of the findings presented at the CROI Conference came from an extension study of a Phase 2b trial that looked into PRO 140 being used as a single agent maintenance therapy for patients with viral suppression after following standard combination antiretroviral therapy.

The study included a total of 42 patients, all of them with CCR5-tropic HIV, who were on stable antiretroviral therapies with undetectable viral load. Participants received weekly subcutaneous injections of PRO 140 for one week only while being on their regular treatments. After the first week, the patients continued only with PRO 140. Twenty-two participants of the 42 maintained viral suppression throughout the main course of the study (12 weeks). From the 16 patients who were given the option to continue with this therapy in an extension arm, 11 are still on this therapy.

Dhody explained that 13 of these 16 patients (or 81 percent) maintained viral suppression for more than 40 weeks. Ten of these (63 percent) maintained suppression for more than two years and were still undergoing PRO 140 monotherapy at the time when the results of the study were released. Of the other patients, five experienced viral rebound after 100 to 700 days, while one person moved away and no longer participated in the study. As for side effects, PRO 140 was safe and well tolerated by patients, with no serious adverse reactions reported.

The results of the study are very encouraging, researchers said, and they support the continued development of this therapy as a single-agent, long-acting treatment for HIV patients who are not satisfied with the quality of life they have with regular antiretroviral therapies as they experience toxicity, intolerance or resistance to them. Maintenance monotherapy with PRO 140 is currently being studied in a larger clinical trial (a Phase 3), as researchers are trying to identify which factors may predict good treatment response.

The other monoclonal antibody therapy discussed at CROI 2017, Ibalizumab, showed modest antiviral activity when administered via IV infusion every two weeks, together with optimized antiretroviral therapy. Compared to PRO 140, Ibalizumab is effective against HIV that uses either CCR5 or CXCR4 co-receptors.

For more information, visit www.CytoDyn.com

With over 40 years of relevant industry experience, National Waste Management Holdings, Inc. (OTC: NWMH) is on a roll. The company continues to execute a roll-up strategy that is paying huge dividends. Since 2014, NWMH has executed five M&A transactions, which have resulted in an increased customer base, a wider menu of services and a bigger top line. Now, the company is focused on increasing shareholder value by squeezing synergies from those acquisitions.

NWMH’s roll-up strategy took off on June 16, 2014, after a reverse merger with Sand/Land of Florida Enterprises, Inc. (“Sandland”), which then became a wholly-owned subsidiary of NWMH. Sandland is a solid waste management company currently operating a licensed construction & demolition (C&D) landfill, with primary operations near Tampa, Florida.

On October 15, 2015, NWMH followed up with the acquisition of Waste Recovery Enterprises, LLC (“WRE”). WRE offers residential trash pickup, commercial and residential dumpster service and roll-off boxes for construction and clean-up projects. The company has a transfer station that accepts C&D debris, household trash, furniture and appliances. The company also offers wood grinding, demolition, and mulch and gravel services. Its primary operations are based near Binghamton, New York.

Then, on December 1, 2015, NWMH acquired Gateway Rolloff Services, LP (“Gateway”), a company with its major operations near Tampa, Florida. Gateway offers commercial and residential dumpster service and roll-off boxes for construction and clean-up projects and specializes in the removal of debris, garbage and waste, particularly as it relates to hauling construction and demolition debris. The Gateway subsidiary is focused on servicing general contractors, new home builders, reconstruction, renovation, landscaping and home improvement professionals.

These two major acquisitions turned NWMH into a full service solid waste management company with operations in Florida and New York, but the expansion continued. In May 2016, NWMH acquired Sivart Services, LLC a roll-off and compactor company located in Worchester, NY, in an all cash transaction. The acquisition expanded NWMH’s footprint in the Northeast and, by linking to the company’s permitted waste facility in Bainbridge, NY, has yielded tremendous synergies.

Earlier this year, NWMH announced another acquisition. On December 31, 2016, the company inked a deal to acquire Northeast Data Destruction and Recycling, LLC, located in Kingston, New York. The transaction was in line with the company’s aggressive acquisition strategy calling for at least one acquisition per quarter. Through this rapid strategic expansion, National Waste Management aims to effectively diversify its revenue streams while moving toward full vertical integration.

NWMH is now a full service waste management company offering landfill, transfer station, garbage collection and container services for both the commercial and residential markets in Central Florida and Upstate New York. NWMH processes approximately 200,000 cubic yards of construction debris per year at its 54-acre landfill facility. The company started operations with one roll-off truck and now operates 13 roll-off trucks and approximately 800 containers. Since the year 2000, NWMH has maintained a contract with Citrus County Solid Waste Management landfill to back-up its roll-off trucks.

For more information, visit the company’s website at www.nationalwastemgmt.com

Let us hear your thoughts: National Waste Management Holdings, Inc. Message Board

Despite the release of many studies, there is still a lot of confusion surrounding cannabidiol, or CBD. CBD is one of over 85 cannabinoids present in the cannabis plant, and, unlike THC, it interacts with our naturally occurring systems without being psychotropic, which means it doesn’t make a person “high”. In the eyes of many, it is thought to be a safer option while offering numerous health benefits.

CBD oil has been shown to help treat anxiety, chronic pain, and diseases such as Crohn’s, cancer, and Parkinson’s, among others. There are a number of types of hemp CBD oil products, many of which are legal across the world. Some of these include pure CBD oils, tinctures, liquids, capsules, and topicals.

There are numerous ways to make CBD oil, each of which has its advantages and disadvantages, with some more effective than others. Some of the most common ways in which companies extract CBD-rich cannabis oil are CO2 extraction, as well as with olive oil and even ethanol, none of which involve the use of neurotoxic solvents like butane or hexane, as these can leave unsafe residues in the body.

Diamond CBD, a subsidiary of PotNetwork Holdings, Inc. (OTC: POTN), has achieved a unique cold manufacturing process that can reproduce the phytochemical profile of original dry hemp material. The company uses Supercritical CO2 extraction to create its CBD oil products, including CBD crystals, dabs, drops, shots, gummies, vapes, and CBD for pets.

Diamond CBD’s manufacturing process uses low temperatures during extraction, allowing it to preserve a large spectrum of beneficial molecules. The company’s production is GMP-certified and uses raw materials that are quality tested, meaning that the production process meets the highest quality standards in the industry.

For more information, visit www.DiamondCBD.com

Cannabis has been used for thousands of years as a form of natural remedy. But, over time, the possession of marijuana was made illegal in many countries, until now. Most recently, a new movement has taken place whereby both the medical and recreational use of cannabis has been legalized across certain states in the U.S. and a number of countries.

The marijuana industry is proving to be important in more ways than one, with Forbes stating that “A new report from New Frontier Data projects that by 2020 the legal cannabis market will create more than a quarter of a million jobs” (http://dtn.fm/64x0J). The article continues to explain that this represents more than the number of jobs generated from manufacturing, government, and utilities.

Despite the changing opinions regarding the drug, China still maintains its stance that cannabis is illegal both recreationally and medically. The possession, transport, cultivation, and sale of cannabis are illegal throughout China, and penalties for cannabis-related offenses are said to be harsh. But cannabis comes in many forms, and although smoking or consuming the drug in any way is illegal, CBD oil for medical purposes has caught the eye of experts across the globe.

As the world continues to make strides toward the legalization of marijuana, demand for CBD oil continues to grow. CBD can be used in a variety of different forms, from sprays to oils and even capsules and concentrates, with expansion toward drops, soft gels, and vapes. CBD oil is being used to treat a number of conditions, including cancer, autism, ADHD, seizures, anxiety, and Crohn’s disease, among others.

According to Forbes (http://dtn.fm/1yVuX), The Hemp Business Journal believes “the CBD market will grow to a $2.1 billion market in consumer sales by 2020 with $450 million of those sales coming from hemp-based sources. That’s a 700% increase from 2016.” And, despite most of the attention being on the United States after propositions for the legalization of marijuana passed in numerous states, organizations from countries across the world are tapping into this growing market.

Last month, ChineseInvestors.com, Inc. (OTCQB: CIIX) announced that it would be launching the first CBD health products store in Chinese. The company is aiming to become the first ever provider of CBD oil products to customers located in mainland China and to Chinese speakers in the United States and Canada. The products will be sold through CIIX’s website: www.ChineseCBDoil.com.

It is clear that ChineseInvestors.com has found a significant gap in the market, with no competition currently on the horizon serving the Chinese speaking population around the world in this way. CBD oil is one of the fastest growing market categories in the hemp and legal marijuana industries, and CIIX has positioned itself for growth thanks to its agreement with a San Diego producer that will be white labeling and distributing the company’s CBD products legally to the entirety of the United States and China.

For more information, visit the company’s website at www.ChineseInvestors.com

DarioHealth Corp. (NASDAQ: DRIO), a company focused on digital and mobile health and targeting diabetes monitoring, received on January 12, 2017, a private placement investment of $2.5 million from OurCrowd Qure, a health care fund focused on digital solutions. The funds will be used by DarioHealth Corp. to grow its share in existing markets and to expand into new ones, such as Germany. The total private placement is $5.1 million (http://dtn.fm/r8Fu4), the company said, of which $2 million will be closed upon future shareholder approval, per NASDAQ rules.

DarioHealth Corp., based in Jerusalem and Boston, manufactures a platform for smart diabetes management. It is a B2C model marketed combination of its Blood Glucose Monitoring System smart phone app and a number of tools to help in health care decisions by users. It is a portal for the internet. In its investor presentation (http://dtn.fm/bm4Ms), the company projects there will be 642 million diabetics globally by 2040, quoting the IDF Diabetes Atlas 7th edition, 2015. DarioHealth Corp. markets fourth generation native mobile devices to monitor blood glucose levels and generate real time health data on its user app. It offers coverage to both Android and iOS devices globally.

In the U.S. alone, DarioHealth Corp. states, the total economic burden of diabetes was $322 billion in 2012. It says some 30 million Americas have the disease and one in five health care dollars is spent in care for people with diabetes. Further, it says the glucose monitoring market is $13 billion and growing at a 5.2% CAGR, according to Research and Markets (http://dtn.fm/hnRZ7). It is seen growing to $24.6 billion by 2020.

The investment transaction will be for 1,821,437 shares of common stock, at a price per share of $2.80. It will also have a warrant to buy 1,821,437 shares of common stock. The five-year warrants will have a price of $3.50 per share. Dario (NASDAQ: DRIO) closed at $4.25 per share on February 24, 2017. If fully exercised for cash, the company said the warrants would generate $6.37 million.

OurCrowd Qure will receive two seats on the board of DarioHealth Corp., to be filled at a later date. Dario’s products have already received regulatory approval in both Europe and the U.S., and it obtains reimbursement in Canada, Italy, Israel, Australia and the United Kingdom. It has expanded into Belgium, the Netherlands and New Zealand. OurCrowd Qure’s investment will enable it to expand into Germany, too. Social media, such as Facebook, is a tool by which DarioHealth Corp. increases its share and penetrates markets, it said.

In a news release, Erez Raphael, chairman and CEO of Dario, said, “We have received great support and belief in our product, vision and growth strategy from investors. With this funding, we will accelerate adoption of our innovative and user-friendly remote glucose monitor platform across current markets and also expand into new geographies, such as Germany, in 2017.”

Allen Kamer, managing partner of OurCrowd Qure, noted that Dario has a global footprint and disrupts health care delivery with its B2C marketing strategy.

For more information, refer to www.MyDario.com

Every company’s success is determined by product, process and people. With unique product offerings in the real estate industry, eXp World Holdings (OTCQB: EXPI) has demonstrated both the need and the desire for its services. Revenue growth of 112% in the last year, and 178% agent expansion during the same period, is a testament to successful product acceptance and use. Process, the efficient execution and delivery of the company’s products and services, is also proven by the numbers. The third and, perhaps, most significant aspect of a successful company is people, most importantly, management.

Management sets the course and culture of a company and is responsible for both product and process. The management team at eXp World Holdings has the background, vision, and expertise to execute the company’s plan efficiently and effectively.

CEO and Chairman of the Board Glenn Sanford accumulated executive level experience with a number of technology-related companies prior to founding eXp World Holdings. About 20 years ago, he founded and led a successful online e-commerce and logistics company, where attention to product and process are paramount. Sanford became active in online real estate in 2002, and, from 2004 to 2007, he led a large team of realtors while specializing in online client acquisition, client conversion and technology. When the real estate boom went bust, Sanford responded by forming eXp Realty in 2009 as the first truly cloud-based national real estate brokerage. His vision, experience, and tenacity still guide the company’s success today.

Sanford has surrounded himself with creative, high caliber executive leadership. Russ Cofano, president and general counsel, has an extensive background in real estate and real estate law, and he has worked at executive levels in nearly every segment of the real estate industry. Cofano is a published and recognized author, public speaker, and a sought-after consultant in real estate matters.

The additions of Jason Gesing, CEO of the Real Estate Division and Board Member, and Vikki Bartholomae, president of the Real Estate Division, dramatically impacted the upsurge in growth of eXp World Holdings. Both senior veterans of the real estate industry, Gesing and Bartholomae bring experienced success to the management team.

Sanford chose an experienced and dedicated CFO in Alan Goldman. Goldman consulted for eXp for three years prior to joining the eXp team. He has extensive experience in public company accounting standards and financial reporting, along with multiple other financial and back office skills.

The board of directors is seasoned, experienced, and well respected, both in the real estate community and beyond. Drawing from varied industries and backgrounds helps keep eXp focused and provides infrastructure for fast paced growth.

With product, process, and exceptional people in place, it’s no wonder that eXp World Holdings has enjoyed such phenomenal growth in recent months.

For more information, visit the company’s website at www.eXpWorldHoldings.com

Let us hear your thoughts: eXp World Holdings, Inc. Message Board

According to a Voyager’s World article (http://dtn.fm/wVHm5), adventure tourism is on the rise because of an increase in disposable income, a change in consumer expectations, improvements in technological infrastructure, and the ability for organizations to tap into the adventure tourism markets.

The article points out that, in earlier reports from 2015, “69% of global travelers aspire to try (something) novel, something that they are previously unaccustomed to, in 2016. This also indicates that millennials plan to be more adventurous by engaging in more challenging activities.”

Adventure activities as we know them have changed, with trekking, hiking, and cycling being augmented or replaced by more extreme activities, such as bungee jumping, rappelling, paragliding, skydiving, and more. Adventurers are now looking for experiences that are both authentic and unique.

With the proliferation and development of the internet, consumers are now able to do in-depth research about nearly all destinations across the world. Despite many opting to book their adventures on their own, travel agents have now made a huge shift to online, meaning that travelers can book all-in-one package holidays from the comforts of one website.

This growing trend comes with a newfound need for safety. Because adventure travel comes with its own risks, adventurers often prefer to organize these activities through trustworthy, licensed companies, many of which offer package holidays that include flights, ground transportation, hotels, tours, and activities.

This is where Monaker Group, Inc. (OTCQB: MKGI) comes in. The technology-focused travel company offers trips to a variety of destinations around the world through its flagship NextTrip.com. The platform caters to all types of travelers, allowing them to book their adventure holidays through NextTrip’s all-in-one travel planner, which works on desktop, mobile devices and tablets.

For more information, visit the company’s website at www.MonakerGroup.com

Headquartered in Largo, Florida, Stealth Technologies (OTCQB: STTH) is focused on the personal and financial protection markets and continuing to capitalize on proprietary products with proven distribution.

Technology and pushing its limits is the fundamental strategy of Stealth Technologies’ operations. A champion of innovation, the company solves some of the most challenging issues in security and personal protection today with its collection of products and intellectual property, focusing on hardware solutions for software problems.

Stealth Technologies is gradually gaining recognition for the 911 Help Now product it has developed to tackle emergency response latency. It facilitates personal safety and security by providing a direct two-way voice connection to emergency service providers, and it is simple to use. After installing standard AAA batteries in the product, consumers can connect to 911 by simply pressing one button — the Help Now button. Owners of the product also enjoy several added features, including an accidental call cancel button and a one-year battery life.

Stealth Technologies first gained prominence because of its focus on product development and sales in the personal financial protection and data protection businesses. Over the years, the company has become well known for its portfolio of products which help consumers protect against credit fraud, cell phone data breaches and electronic pickpockets. The company’s lead product, the Stealth Card, for example, is one product that is designed to protect the Europay, MasterCard and Visa (EMV) chip in a consumer’s credit card from electronic pickpockets who attempt to use a smartphone, credit card reader or radio-frequency identification (RFID) antenna to remotely access the data stored on this smart chip.

Stealth Technologies continues to develop even more products, while exploring potential commercialization opportunities and military applications for its existing proprietary technologies.

For more information, visit www.TechnologiesByStealth.com

Let us hear your thoughts: Stealth Technologies Inc. Message Board